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• Atenolol, verapamil and norverapamil were extracted from plasma and 
aqueous buffer matrices using various organic solvents; following which tert-
butyl-methyl ether and iso-propanol mixture (4:1) was selected.
• The sample preparation and analytical methods described here are suitably 
efficient, sensitive, precise and accurate to simultaneously measure levels of 
atenolol, verapamil and norverapamil.
• The methods can be used following single-pass in situ jejunal perfusion with an 
atenolol/verapamil drug cocktail to measure drug and metabolite levels in the 
mesenteric plasma as well as lumenal perfusate. 
MS and MS/MS Scans:  Each analyte was solubilized in 50% acetonitrile at a concentration of 20 
µg/mL.  Solutions were infused (5 µL/min) combined with a mobile phase flow path (50:50 
acetonitrile:water, containing 0.1% formic acid) into a triple quadrapole mass spectrometer 
(QuatroMicro, Waters).  Instrument settings include: cone voltage = 40-55V,  source temperature = 
100° C, desolvation temperature = 300-400° C, cone gas = 60 L/hr. MS and MS/MS spectra were 
collected and product-ions were selected for subsequent multiple reaction monitoring (MRM) 
analyses.
Chromatography: Solutions of atenolol, verapamil, norverapamil (Sigma-Aldrich, St. Louis, MO) and 
metoprolol (internal standard, Sigma-Aldrich) in mobile phase were injected (20 µL) on an Alliance 
HPLC (Waters, Milford, MA) and chromatographed on a Zorbax Eclipse XDB-C18 column (2.1 x 50 
mm, 3.5 mm, Agilent Technologies) using an isocratic acetontrile elution method.  Following the 
testing of various mobile phase compositions, 30% acetontrile (containing 0.1% v/v formic acid), at 
0.4 mL/min, was used in subsequent chromatography.
Sample preparation: Rat plasma or buffered perfusate solution were spiked with 1 µM each of 
atenolol, verapamil and norverapamil (AVN).   Samples (200 µL) of each spiked matrix were 
alkalinized with an equal volume of NaOH (5 M), to which 1 mL of extraction solvent was added.  
Samples were vigorously vortexed (10 min) and centrifuged (1500 rcf, 5 min).  Organic solvent was 
transferred to clean tubes, dried, reconstituted in mobile phase, chromatographed and detected by 
MRM analyses (atenolol: 267  145 m/z; verapamil: 455  165 m/z; norverapamil: 441  165 m/z).  
As a measure of extraction efficiencies, absolute peak areas were compared to those of 1 µM AVN 
solutions in mobile phase.  For subsequent studies matrix standards and experimental gut 
perfusion samples were extracted using tBME:iso-propanol (4:1) containing metoprolol (268  145 
m/z) as an internal standard. 
• To develop a sample preparation and analytical detection method to 
simultaneously measure atenolol and verapamil along with the N-demeth-
ylated metabolite, norverapamil, in rat plasma and aqueous buffered matrices.
• To use this method in measuring levels of all three analytes in plasma and 
lumenal perfusate samples following in situ rat intestinal perfusion of an
atenolol-verapamil drug cocktail formulation.
The preclinical development of drug candidates often requires laboratory animals 
to be orally administered a test compound in a solution or suspension containing a 
high concentration of excipient.  However, recent in vitro studies suggest that 
commonly used excipients (e.g., polyethylene glycol) may affect intestinal first-
pass elimination mechanisms such as P-gp and cytochrome P450 (CYP) (1-4).  To 
evaluate the effects of excipients on rat intestinal P-gp and CYP, an in situ single-
pass intestinal perfusion method will be employed using verapamil as a marker of
transcellular metabolism/permeation and atenolol as a marker of paracellular 
permeation.
Atenolol (pKa 9.4 (5); log P = 0.16 (6)) and verapamil (pKa 8.9 (7); logP = 3.8 (6)) 
will be experimentally administered in a ‘cocktail’ formulation and therefore 
simultaneous analysis of the resulting plasma and perfusate samples will be 
necessary.  Both molecules are soluble in water or low concentrations of organic 
solvent (e.g., methanol), however, based on the greater lipophilicity of verapamil 
(higher logP) we expect different sample preparation (e.g., extraction) 
requirements from that of atenolol.  Other labs have demonstrated reliable sample 
preparation methods followed by HPLC-UV and HPLC-MS/MS detection 
methods for either atenolol or verapmil (8-10).  However, we are aware of no 
published method that describes the simultaneous extraction and quantitative 
measurement of both these drug molecules.  Therefore, it is necessary to develop a 
suitably sensitive, precise and accurate method that allows for the simultaneous 
measurement of both molecules from the relevant experimental matrices, rat 







2.1 x 50 mm, 3.5 µm Zorbax XDB C18; x% acetonitrile, 0.2 mL/minFigure 2. The effect of mobile phase strength (ε) on 
the retention time of four analytes:  atenolol
(maroon), metoprolol (black), norverapamil 
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Figure 3. The effect of solvent composition on the liquid-liquid extraction efficiency of 
atenolol (A), verapamil (V) and norverapamil (N) from two matrices, rat plasma 
and buffered lumenal perfusate (gut buffer).  tBME:iso-propanol (4:1) was 








Figure 1. Electrospray ionization (positive ion mode) mass spectra (MS, shown in green) 
and MS/MS product-ion spectra (shown in red) of (A) atenolol (m/z 266), (B) 
verapamil (m/z 455) and (C) norverapamil (m/z 441) in 50% acetonitrile 
containing 0.1% (v/v) formic acid.  Each MS/MS scan was performed using the 
appropriate set mass (parent m/z) resulting in the respective product ion 
spectra.  Arrows indicate the product-ion that was selected in each case for 
subsequent quantitative (MRM) analyses.  Predicted fragment-structure for 
atenolol was rationalized based on exact mass measurements (145.0653; 
C10H9O, 4.5 ppm) whereas predicted fragment-structure for verpamil and 







































Nominal Calc. Accuracy CV Nominal Calc. Accuracy CV Nominal Calc. Accuracy CV
50 46 91.6% 10.3% 5 5 100.5% 8.2% 5 6 111.1% 23.1%
100 94 94.0% 25.6% 25 24 96.3% 9.0% 25 29 114.9% 10.5%
500 477 95.4% 7.7% 50 47 93.1% 1.5% 50 51 102.9% 7.3%
1000 1022 102.2% 3.1% 250 276 110.5% 3.8% 250 259 103.8% 8.3%
Statistical weighting: None 500 546 109.2% 1.8% 500 566 113.2% 5.4%
r^2 = 0.998103 2500 2498 99.9% 3.1% 2500 2426 97.1% 4.6%
5000 5013 100.3% 1.3% 5000 4631 92.6% 2.2%
Statistical weighting: 1/x Statistical weighting: 1/x
Coefficient of Determination: 0.993212 Coefficient of Determination: 0.999100
PERFUSATE STANDARDS
Nominal Calc. Accuracy CV Nominal Calc. Accuracy CV Nominal Calc. Accuracy CV
500 472 94.4% 32.0% 1000 1030 103.0% 7.3% 500 294 58.8% 3.1%
1000 952 95.2% 25.7% 2000 1922 96.1% 3.6% 1000 1108 110.8% 4.2%
5000 4359 87.2% 33.1% 10000 7952 79.5% 1.6% 5000 5129 102.6% 6.5%
10000 9228 92.3% 14.7% 20000 19652 98.3% 3.5% 10000 9413 94.1% 5.9%
Statistical weighting: None Statistical weighting: 1/x Statistical weighting: 1/x
r^2 = 0.996247 Coefficient of Determination: 0.991056 Coefficient of Determination: 0.999788
[Verapamil] (nM) [Norverapamil] (nM)Averages; n=3 Averages; n=3 Averages; n=3
[Atenolol] (nM) Averages; n=3 [Verapamil] (nM) Averages; n=3 [Norverapamil] (nM) Averages; n=3
[Atenolol] (nM)
Table 1. Samples of rat plasma or perfusate buffer were spiked with mixtures of 
atenolol, verapamil and norverapamil (reported as ‘nominal’ concentration) 
and subjected to liquid-liquid extraction with tBME:iso-propanol (4:1).  
Samples were either extracted (a) directly (1x) or diluted (b) 5x, (c) 10x or (d) 
20x prior to extraction to obtain signal intensities within the linear range of 
the instrument.  Extracted samples were dried, reconstituted in 30% 
acetonitrile, 70% water (containing 0.1% formic acid) and analyzed by HPLC-
MS/MS according to the methods described here.  Calculated concentrations 
(calc.) from the respective standard curves are reported along with accuracy 























































Figure 4. Measured levels of atenolol, verapamil and 
norverapamil in (A) rat plasma and (B) lumenal
perfusate following in situ perfusion of rat 
jejunum with an atenolol/verapamil 
(each 20 µM) cocktail formulation.
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